Source: Eur Respir J 2012; 40: 500-503
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Sotgiu Giovanni, D'Ambrosio Lia, Centis Rosella, Bothamley Graham, Cirillo Daniela M., De Lorenzo Saverio, Guenther Gunar, Kliiman Kai, Muetterlein Ralf, Spinu Victor, Villar Miguel, Zellweger Jean-Pierre, Sandgren Andreas, Huitric Emma, Lange Christoph, Manissero Davide, Migliori Giovanni Battista. Availability of anti-tuberculosis drugs in Europe. Eur Respir J 2012; 40: 500-503

Member's Comments

No comment yet.

Related content which might interest you: Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe Source: Eur Respir J, 58 (3) 2101196; 10.1183/13993003.01196-2021 Year: 2021 Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey Source: Eur Respir J 2015; 45: 1081-1088 Year: 2015 New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015 Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021 Availability of PCR for second-line drugs in Europe Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016 Anti-tuberculosis drugs Source: International Congress 2017 – State of the art session: "Respiratory infections" Year: 2017 Drug resistant pattern of antitubercular drugs in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy Source: Eur Respir J 2012; 39: 1263-1266 Year: 2012 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 New anti-tuberculosis drugs for special populations: a difficult-to-address issue Source: Eur Respir J 2016; 48: 957-958 Year: 2016 Rational use of new TB drugs in the EU Source: Annual Congress 2012 - New guidelines in respiratory infections Year: 2012 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 Increasing anti-tuberculosis drug resistance in the UK Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Resistance rates of Mycobacterium tuberculosis to first-line antituberculosis drugs. Trends in Greece during the period 1991–2000 Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008